J. Tie

J. Tie, A. Heriot, C. Hewitt, 2022, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis

J. Tie, A. Heriot, P. Waters, 2022, Annals of Surgical Oncology.

Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.

J. Tie, R. Ramsay, M. Michael, 2019, Diseases of the colon and rectum.

Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases

J. Tie, R. Ramsay, M. Michael, 2019, Langenbeck's Archives of Surgery.

Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.

P. Gibbs, J. Tie, H. Wong, 2016 .

Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status

P. Gibbs, L. Lipton, J. Tie, 2013 .

Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).

T. Yeatman, R. Jorissen, P. Gibbs, 2014 .

Author reply

P. Gibbs, J. Tie, 2013, Internal medicine journal.

Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms

J. Tie, R. Ramsay, M. Michael, 2019, ANZ journal of surgery.

Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience

J. Tie, T. Akhurst, R. Ramsay, 2019, Journal of Gastrointestinal Surgery.

The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).

K. Kinzler, B. Vogelstein, P. Gibbs, 2017 .

A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.

P. Gibbs, J. Desai, B. Solomon, 2017 .

Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS)

Suzanne G. Orchard, P. Gibbs, R. Woods, 2022, medRxiv.

Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial

J. Tie, M. IJzerman, I. Campbell, 2022, Acta oncologica.

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

T. Yeatman, R. Jorissen, P. Gibbs, 2015, Acta oncologica.

Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.

P. Gibbs, A. Burgess, J. Tie, 2019, Growth factors.

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC Trial): Statistical Analysis Plan

B. Vogelstein, P. Gibbs, J. Cohen, 2021, medRxiv.

Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer

P. Gibbs, J. Tie, M. IJzerman, 2021, PharmacoEconomics.

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

D. Jäger, M. Shah, E. Rasmussen, 2020, Journal for ImmunoTherapy of Cancer.

Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.

P. Gibbs, M. Christie, J. Tie, 2017, Seminars in cancer biology.

RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer.

J. Tie, C. Karapetis, D. Maru, 2016, Clinical colorectal cancer.

Circulating Levels of the Wnt Antagonist Dkk-3 as a Diagnostic Markerfor Colorectal Cancer

P. Gibbs, B. Tabor, J. Tie, 2012 .

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies

J. Desai, J. Tie, 2015, Targeted Oncology.

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

M. Makary, S. Hanash, Song-Cheol Kim, 2017, Proceedings of the National Academy of Sciences.

Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria

P. Gibbs, M. Christie, J. Desai, 2016, International journal of cancer.

Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine.

P. Gibbs, J. Tie, 2016, Clinical chemistry.

Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy

Shalini C. Pereira, J. Tie, C. Grandori, 2020, Clinical Cancer Research.

Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer.

J. Ptak, K. Kinzler, B. Vogelstein, 2019, JAMA oncology.

Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma

P. Gibbs, J. Tie, Belinda Lee, 2019, Journal of personalized medicine.

CD8+ tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival

S. Fox, P. Gibbs, J. Desai, 2020, Clinical & translational immunology.

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

P. Gibbs, J. Desai, O. Sieber, 2011, Cancer.

Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival.

P. Gibbs, J. Desai, J. Tie, 2015, Clinical colorectal cancer.

The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.

R. Strausberg, K. Kinzler, B. Vogelstein, 2016 .

Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation

R. Jorissen, P. Gibbs, M. Christie, 2011, International journal of cancer.

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late

R. Tothill, S. Dawson, J. Tie, 2021, Diagnostics.

ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm

P. Gibbs, J. Tie, M. Naidoo, 2021, Cancers.

Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

E. Van Cutsem, J. Tabernero, A. Grothey, 2022, JCO precision oncology.

Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?

J. Tie, Oliver Piercey, M. Naidoo, 2021, Current Oncology Reports.

Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic

P. Gibbs, J. Tie, A. Jalali, 2019, Oncology & Hematology Review (US).

Effect of Aspirin on Cancer Incidence and Mortality in Older Adults

Suzanne G. Orchard, C. Reid, J. McNeil, 2020, Journal of the National Cancer Institute.

Prediction of disability-free survival in healthy older people

Michael S. Warren, H. C. Siew, Suzanne G. Orchard, 2022, GeroScience.

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer

P. Gibbs, M. Christie, J. Desai, 2017, Internal medicine journal.

Clinical guidance for radioiodine refractory differentiated thyroid cancer

J. Tie, J. Walsh, B. Hughes, 2018, Clinical endocrinology.

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer

P. Gibbs, J. Desai, O. Sieber, 2014, Targeted Oncology.

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Y. Bang, Yoon-Koo Kang, J. Tie, 2017, Targeted Oncology.

The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern

P. Gibbs, D. Roder, J. Tie, 2018, Acta oncologica.

Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials

P. Gibbs, J. Tie, 2013, Internal medicine journal.

Systemic Inflammation - Impact on Tumor Biology and Outcomes in Colorectal Cancer

P. Gibbs, J. Desai, J. Tie, 2015 .

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer

J. Tie, C. Karapetis, D. Maru, 2015, Expert review of molecular diagnostics.

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

J. Ptak, K. Kinzler, B. Vogelstein, 2020, International journal of cancer.

Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases.

P. Gibbs, J. Tie, R. Wong, 2021, Clinical colorectal cancer.

Differentiation of tumor recurrence from radiation necrosis in high-grade gliomas using 201Tl-SPECT

Dishan H. Gunawardana, J. Tie, M. Rosenthal, 2008, Journal of Clinical Neuroscience.

Second primary colorectal cancer in the era of prevalent screening and imaging

P. Gibbs, J. Tie, I. Jones, 2013, ANZ journal of surgery.

Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC).

R. Jorissen, P. Gibbs, L. Lipton, 2013 .

O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies

J. Tabernero, J. Tie, T. George, 2021, Annals of Oncology.

Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond.

P. Gibbs, M. Christie, J. Tie, 2018, Future oncology.

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

Roger Berry, Peter Gibbs, Robert L Strausberg, 2011, Clinical Cancer Research.

Redefining Colorectal Cancer by Tumor Biology.

J. Tie, M. Salem, A. Puccini, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.

P. Gibbs, J. Desai, J. Tie, 2016, Clinical colorectal cancer.

Assessing aneuploidy with repetitive element sequencing

Tian-Li Wang, Rachel Karchin, Robert E. Schoen, 2019, Proceedings of the National Academy of Sciences.

The predictive value of PET/CT for distant recurrences in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

J. Tie, M. Michael, T. Akhurst, 2021, Journal of medical imaging and radiation oncology.

400a – Effect of Initiating Aspirin on Cancer Events in the Healthy Elderly: Primary Results from the Aspree Randomized Controlled Trial

P. Gibbs, J. McNeil, L. Ford, 2019, Gastroenterology.

Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?

J. Tie, Oliver Piercey, 2023, Therapeutic advances in medical oncology.

A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol

V. Gebski, J. Tie, C. Karapetis, 2022, BMC cancer.

Reply to: Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not

J. Tie, A. Heriot, S. Ngan, 2021, Annals of Surgical Oncology.

Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies

P. Gibbs, J. Tie, H. Wong, 2020, Visceral Medicine.

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies

P. Gibbs, M. Christie, J. Tie, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer

B. LaFleur, P. Gibbs, J. Desai, 2016, Clinical Cancer Research.

Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study

J. Ptak, K. Kinzler, B. Vogelstein, 2021, PLoS medicine.

The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern.

P. Gibbs, D. Roder, J. Tie, 2017 .

Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.

J. Tie, M. Alexander, S. Lingaratnam, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)

B. Vogelstein, P. Gibbs, J. Cohen, 2022, Annals of Oncology.

Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.

N. Pavlakis, J. Tie, D. Goldstein, 2019, Journal of Clinical Oncology.

Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands

J. Ptak, K. Kinzler, B. Vogelstein, 2021, Nature Biotechnology.

Re‐inventing the randomized controlled trial in medical oncology: The registry‐based trial

P. Gibbs, A. Burgess, J. Tie, 2018, Asia-Pacific journal of clinical oncology.

Management of Distant Metastasis in Differentiated Thyroid Cancer

J. Miller, J. Tie, D. Pattison, 2018 .

Registry‐based randomized clinical trials as a method to improve cancer care in Australia

P. Gibbs, A. Burgess, J. Tie, 2019, Asia-Pacific Journal of Clinical Oncology.

Glucagonoma Masquerading as a Mucinous Cancer of the Ovary: Lessons from Cell Biology

Kylie L. Gorringe, D. Bowtell, J. Tie, 2020, Gynaecological Malignancies - Updates and Advances.

Real‐world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer

P. Gibbs, J. Tie, I. Jones, 2022, Asia-Pacific journal of clinical oncology.

The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations

K. Kinzler, B. Vogelstein, P. Gibbs, 2019, International journal of cancer.

Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).

K. Kinzler, B. Vogelstein, P. Gibbs, 2018 .

Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?

P. Gibbs, J. Tie, C. Semira, 2018, Expert review of molecular diagnostics.

Triaging suspected cancer with a multi-cancer early detection blood test.

J. Tie, 2023, The Lancet. Oncology.

Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.

K. Kinzler, B. Vogelstein, P. Gibbs, 2018 .

Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM).

R. Strausberg, K. Kinzler, B. Vogelstein, 2016 .

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review

P. Gibbs, J. Tie, M. IJzerman, 2023, Cost Effectiveness and Resource Allocation.

Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients.

P. Gibbs, B. Tabor, J. Tie, 2013, Cancer biomarkers : section A of Disease markers.

Clinical application of circulating tumour DNA in colorectal cancer.

P. Gibbs, J. Tie, M. Loft, 2023, The lancet. Gastroenterology & hepatology.

Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)

P. Gibbs, J. Desai, J. Tie, 2013 .

Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?

P. Gibbs, L. Lipton, J. Tie, 2019, Internal medicine journal.

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

P. Gibbs, J. Desai, S. Dawson, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer. Reply.

P. Gibbs, J. Tie, S. Lo, 2022, New England Journal of Medicine.

Low intensity treatment in metastatic colorectal cancer.

J. Tie, H. Wong, 2022, The lancet. Gastroenterology & hepatology.

Real‐world outcomes for neoadjuvant capecitabine versus infusional 5‐fluorouracil in the treatment of locally advanced rectal cancer

P. Gibbs, M. Christie, J. Tie, 2020, Internal medicine journal.

Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia

P. Gibbs, J. Desai, J. Tie, 2015, Asia-Pacific journal of clinical oncology.

Selecting subjects for a therapeutic target in colorectal cancer (CRC): Using a clinical database to enrich for patients harboring the BRAFV600E mutation.

R. Jorissen, P. Gibbs, L. Lipton, 2009, Journal of Clinical Oncology.

Abstract CT058: Phase I study of LY2874455, a fibroblast growth factor (FGF) receptor inhibitor, in patients with advanced cancer

Y. Bang, Yoon-Koo Kang, J. Tie, 2016 .

Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cance

Y. Bang, Yoon-Koo Kang, J. Tie, 2014 .

Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice

P. Gibbs, J. Desai, J. Tie, 2014, Asia-Pacific journal of clinical oncology.

Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation

R. Jorissen, P. Gibbs, M. Christie, 2011, International journal of cancer.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre

J. Tie, A. Heriot, P. Waters, 2022, ANZ journal of surgery.

Second primary colorectal cancer in the era of prevalent screening and imaging

P. Gibbs, J. Tie, I. Jones, 2013, ANZ journal of surgery.

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

Tae Won Kim, J. Tie, K. Yeh, 2021, Journal of Clinical Oncology.

Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans

J. Tie, Peter Gibbs, Yonghong Li, 2024, JAMA health forum.

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

J. Tie, M. Peeters, S. Siena, 2023, Journal of Clinical Oncology.

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities.

J. Tie, Oliver Piercey, Hui-Li Wong, 2024, Clinical colorectal cancer.

Circulating Tumour DNA Guided Adjuvant Chemotherapy Decision Making in Stage II Colon Cancer—A Clinical Vignette Study

J. Tie, J. Loree, K. Degeling, 2023, Cancers.

Early onset metastatic colorectal cancer in Australia.

J. Tie, S. Kosmider, B. Lee, 2024, Cancer treatment and research communications.

Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer

J. Tie, S. Kosmider, Margaret Lee, 2022, Internal medicine journal.

Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's

J. Tie, L. Bester, Jeanne Tie, 2015 .